In the Phase 3 TEMPO program, AbbVie’s Juvmo elicited significant improvements in motor symptoms and prolonged periods with ...

Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.

Some people live with essential tremor for years and organically find ways to adapt. Others may begin avoiding activities.

FDA gives go-ahead to D1/D5 dopamine agonist tavapadon ...

Gain Therapeutics’ lead drug candidate rexaceract, formerly known as GT-02287, is in clinical development for the treatment ...

Target Price (Mid): ~$363Street Target: ~$279Potential Total Return: ~37%Annualized IRR: ~8% / yearWhat Happened?The FDA ...

The FDA approved AbbVie’s once-daily oral drug Juvmo (tavapadon) for adults with Parkinson’s disease. Phase 3 trials found ...

AbbVie stock (ABBV) slipped slightly on Monday, down 0.29%, after the company announced a major regulatory win. The FDA ...

On Monday, Sept. 28, the U.S. Food and Drug Administration approved a new treatment that targets dopamine pathways critical to those living with the disease.

A small study found disease-related odor compounds may show up in skin samples, including from the navel, but much larger trials are needed.

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...